Results 91 to 100 of about 10,116 (190)
Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 4, August 2026.ABSTRACT Intermuscular adipose tissue (IMAT) refers to adipose tissue located between muscle groups or beneath the muscle fascia, and its accumulation is closely linked to impaired muscle quality, reduced contractile function, and adverse metabolic profiles, establishing it as a core component of myosteatosis.
Feier Ding +9 more
wiley +1 more source
Archives of Public HealthBackground and objectives The association between possible sarcopenia, sarcopenia and sarcopenic obesity on multimorbidity risk remains poorly investigating.
Kaixin Zhang, Xiaowei Zheng, Tao Ma
doaj +1 more source
The diagnosis and treatment of sarcopenia and sarcopenic obesity
Deutsches Ärzteblatt internationalSarcopenia is a progressive, generalized disease of skeletal muscle characterized by a loss of muscle strength and muscle mass. The combination of obesity and sarcopenia is called sarcopenic obesity. Because of the aging of the population in many countries around the world, sarcopenia and sarcopenic obesity are a challenge for global health policy.This
Habboub, Basel +3 more
openaire +3 more sources
Future of CT body composition research: Methodological discrepancies and advances
Nutrition in Clinical Practice, Volume 41, Issue 4, Page 1020-1047, August 2026.Abstract Body composition research utilizing computed tomography (CT) has increased over the past several decades as researchers use clinically acquired CT for opportunistic screening or the identification of phenotypes such as sarcopenia, myosteatosis, and sarcopenic obesity associated with various clinical outcomes.
Cecily A. Byrne, Sandra L. Gomez
wiley +1 more source
Sarcopenic Obesity and Endocrinal Adaptation with Age
International Journal of Endocrinology, 2013 In normal aging, changes in the body composition occur that result in a shift toward decreased muscle mass and increased fat mass. The loss of muscle mass that occurs with aging is termed sarcopenia and is an important cause of frailty, disability, and ...
Kunihiro Sakuma, Akihiko Yamaguchi
doaj +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.ABSTRACT Aging is a systems‐level process linking metabolic dysfunction, inflammation, impaired repair, frailty, and multimorbidity, whereas existing pharmacological strategies usually optimize disease‐specific endpoints such as weight loss or HbA1c rather than aging‐related trajectories. We developed an SBML‐compliant quantitative systems pharmacology
Igor Goryanin, Bob Damms, Irina Goryanin
wiley +1 more source
Clinical Obesity, Volume 16, Issue 4, August 2026.ABSTRACT The aim of this study was to evaluate the association between indices of adiposity and 20‐year cumulative incidence of type 2 diabetes (T2D) among apparently healthy adults participating in the ATTICA cohort study (2002–2022). The present analysis included data from 2000 individuals free of atherosclerotic cardiovascular disease (ASCVD) and ...
Ioanna Kechagia +7 more
wiley +1 more source
Resilience of patients with sarcopenic obesity and age-related ocular pathology
Российский офтальмологический журналCataract in combination with sarcopenic obesity, which is formed mainly against the background of physical inactivity due to vision deficiency, potentially contributes to a decrease in vitality, however, the study of the vitality of patients with ...
A. E. Kopylov +3 more
doaj +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6595-6606, August 2026.ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote +10 more
wiley +1 more source